Π‘ΠΏΠΈΡΠΎΠΊ ΡΠΎΠΊΡΠ°ΡΠ΅Π½ΠΈΠΉ.
ΠΡΠ΅Π½ΠΊΠ° ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ Π»Π΅ΡΠ΅Π½ΠΈΡ Π±Π΅ΡΠΏΠ»ΠΎΠ΄ΠΈΡ ΠΌΠ΅ΡΠΎΠ΄Π°ΠΌΠΈ Π²ΡΠΏΠΎΠΌΠΎΠ³Π°ΡΠ΅Π»ΡΠ½ΡΡ
ΡΠ΅ΠΏΡΠΎΠ΄ΡΠΊΡΠΈΠ²Π½ΡΡ
ΡΠ΅Ρ
Π½ΠΎΠ»ΠΎΠ³ΠΈΠΉ Ρ ΠΆΠ΅Π½ΡΠΈΠ½ Ρ ΡΠΈΠ½Π΄ΡΠΎΠΌΠΎΠΌ ΠΏΠΎΠ»ΠΈΠΊΠΈΡΡΠΎΠ·Π½ΡΡ
ΡΠΈΡΠ½ΠΈΠΊΠΎΠ²
ΠΠΠ’ — ΠΈΠ½Π΄Π΅ΠΊΡ ΠΌΠ°ΡΡΡ ΡΠ΅Π»Π° ΠΠΠ — ΠΊΠΎΠΌΠ±ΠΈΠ½ΠΈΡΠΎΠ²Π°Π½Π½ΡΠ΅ ΠΎΡΠ°Π»ΡΠ½ΡΠ΅ ΠΊΠΎΠ½ΡΡΠ°ΡΠ΅ΠΏΡΠΈΠ²Ρ ΠΠ§Π — ΠΌΠΎΡΠ΅Π²ΡΠ΅ Π³ΠΎΠ½Π°Π΄ΠΎΡΡΠΎΠΏΠΈΠ½Ρ ΠΠΠ»ΡΡΠ΅ΠΈΠ½ΠΈΠ·ΠΈΡΡΡΡΠΈΠΉ Π³ΠΎΡΠΌΠΎΠ½ ΡΠ€Π‘Π — ΡΠ΅ΠΊΠΎΠΌΠ±ΠΈΠ½Π°Π½ΡΠ½ΡΠΈ? ΡΠΎΠ»Π»ΠΈΠΊΡΠ»ΠΎ-ΡΡΠΈΠΌΡΠ»ΠΈΡΡΡΡΠΈΠΈ? Π³ΠΎΡΠΌΠΎΠ½ Π‘ΠΠ― — ΡΠΈΠ½Π΄ΡΠΎΠΌ Π³ΠΈΠΏΠ΅ΡΡΡΠΈΠΌΡΠ»ΡΡΠΈΠΈ ΡΠΈΡΠ½ΠΈΠΊΠΎΠ² Π‘ΠΠΠ― — ΡΠΈΠ½Π΄ΡΠΎΠΌ ΠΏΠΎΠ»ΠΈΠΊΠΈΡΡΠΎΠ·Π½ΡΡ ΡΠΈΡΠ½ΠΈΠΊΠΎΠ² Π£ΠΠ — ΡΠ»ΡΡΡΠ°Π·Π²ΡΠΊΠΎΠ²ΠΎΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ ΡΠΠ — ΡΠ΅Π»ΠΎΠ²Π΅ΡΠ΅ΡΠΊΠΈΠ΅ ΠΌΠ΅Π½ΠΎΠΏΠ°ΡΠ·Π°Π»ΡΠ½ΡΠ΅ Π³ΠΎΠ½Π°Π΄ΠΎΡΡΠΎΠΏΠΈΠ½Ρ ΠΠΠ — ΡΠΊΡΡΡΠ°ΠΊΠΎΡΠΏΠΎΡΠ°Π»ΡΠ½ΠΎΠ΅ ΠΎΠΏΠ»ΠΎΠ΄ΠΎΡΠ²ΠΎΡΠ΅Π½ΠΈΠ΅. ΠΠΠ½Π Π — Π°Π³ΠΎΠ½ΠΈΡΡΡ… Π§ΠΈΡΠ°ΡΡ Π΅ΡΡ >
Π‘ΠΏΠΈΡΠΎΠΊ ΡΠΎΠΊΡΠ°ΡΠ΅Π½ΠΈΠΉ. ΠΡΠ΅Π½ΠΊΠ° ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ Π»Π΅ΡΠ΅Π½ΠΈΡ Π±Π΅ΡΠΏΠ»ΠΎΠ΄ΠΈΡ ΠΌΠ΅ΡΠΎΠ΄Π°ΠΌΠΈ Π²ΡΠΏΠΎΠΌΠΎΠ³Π°ΡΠ΅Π»ΡΠ½ΡΡ ΡΠ΅ΠΏΡΠΎΠ΄ΡΠΊΡΠΈΠ²Π½ΡΡ ΡΠ΅Ρ Π½ΠΎΠ»ΠΎΠ³ΠΈΠΉ Ρ ΠΆΠ΅Π½ΡΠΈΠ½ Ρ ΡΠΈΠ½Π΄ΡΠΎΠΌΠΎΠΌ ΠΏΠΎΠ»ΠΈΠΊΠΈΡΡΠΎΠ·Π½ΡΡ ΡΠΈΡΠ½ΠΈΠΊΠΎΠ² (ΡΠ΅ΡΠ΅ΡΠ°Ρ, ΠΊΡΡΡΠΎΠ²Π°Ρ, Π΄ΠΈΠΏΠ»ΠΎΠΌ, ΠΊΠΎΠ½ΡΡΠΎΠ»ΡΠ½Π°Ρ)
Π°ΠΠ½Π Π — Π°Π³ΠΎΠ½ΠΈΡΡΡ Π³ΠΎΠ½Π°Π΄ΠΎΡΡΠΎΠΏΠΈΠ½-ΡΠΈΠ»ΠΈΠ·ΠΈΠ½Π³ Π³ΠΎΡΠΌΠΎΠ½Π° ΠΠΠ’ — Π°Π½ΡΠΈΠΌΡΠ»Π»Π΅ΡΠΎΠ² Π³ΠΎΡΠΌΠΎΠ½ ΠΠ Π’ — Π²ΡΠΏΠΎΠΌΠΎΠ³Π°ΡΠ΅Π»ΡΠ½ΡΠ΅ ΡΠ΅ΠΏΡΠΎΠ΄ΡΠΊΡΠΈΠ²Π½ΡΠ΅ ΡΠ΅Ρ Π½ΠΎΠ»ΠΎΠ³ΠΈΠΈ ΠΠ½Π Π — Π³ΠΎΠ½Π°Π΄ΠΎΡΡΠΎΠΏΠΈΠ½ ΡΠ΅Π»ΠΈΠ·ΠΈΠ½Π³ Π³ΠΎΡΠΌΠΎΠ½ ΠΠΠΠ-Π‘ — Π΄Π΅Π³ΠΈΠ΄ΡΠΎΡΠΏΠΈΠ°Π½Π΄ΡΠΎΡΡΠ΅Π½Π΄ΠΈΠΎΠ½-ΡΡΠ»ΡΡΠ°Ρ ΠΠΠ‘Π (ICSI) — ΠΈΠ½ΡΡΠ°ΡΠΈΡΠΎΠΏΠ»Π°Π·ΠΌΠ°ΡΠΈΡΠ΅ΡΠΊΠ°Ρ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΡ ΡΠΏΠ΅ΡΠΌΠ°ΡΠΎΠ·ΠΎΠΈΠ΄Π°.
ΠΠΠ’ — ΠΈΠ½Π΄Π΅ΠΊΡ ΠΌΠ°ΡΡΡ ΡΠ΅Π»Π° ΠΠΠ — ΠΊΠΎΠΌΠ±ΠΈΠ½ΠΈΡΠΎΠ²Π°Π½Π½ΡΠ΅ ΠΎΡΠ°Π»ΡΠ½ΡΠ΅ ΠΊΠΎΠ½ΡΡΠ°ΡΠ΅ΠΏΡΠΈΠ²Ρ ΠΠ§Π — ΠΌΠΎΡΠ΅Π²ΡΠ΅ Π³ΠΎΠ½Π°Π΄ΠΎΡΡΠΎΠΏΠΈΠ½Ρ ΠΠΠ»ΡΡΠ΅ΠΈΠ½ΠΈΠ·ΠΈΡΡΡΡΠΈΠΉ Π³ΠΎΡΠΌΠΎΠ½ ΡΠ€Π‘Π — ΡΠ΅ΠΊΠΎΠΌΠ±ΠΈΠ½Π°Π½ΡΠ½ΡΠΈ? ΡΠΎΠ»Π»ΠΈΠΊΡΠ»ΠΎ-ΡΡΠΈΠΌΡΠ»ΠΈΡΡΡΡΠΈΠΈ? Π³ΠΎΡΠΌΠΎΠ½ Π‘ΠΠ― — ΡΠΈΠ½Π΄ΡΠΎΠΌ Π³ΠΈΠΏΠ΅ΡΡΡΠΈΠΌΡΠ»ΡΡΠΈΠΈ ΡΠΈΡΠ½ΠΈΠΊΠΎΠ² Π‘ΠΠΠ― — ΡΠΈΠ½Π΄ΡΠΎΠΌ ΠΏΠΎΠ»ΠΈΠΊΠΈΡΡΠΎΠ·Π½ΡΡ ΡΠΈΡΠ½ΠΈΠΊΠΎΠ² Π£ΠΠ — ΡΠ»ΡΡΡΠ°Π·Π²ΡΠΊΠΎΠ²ΠΎΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ ΡΠΠ — ΡΠ΅Π»ΠΎΠ²Π΅ΡΠ΅ΡΠΊΠΈΠ΅ ΠΌΠ΅Π½ΠΎΠΏΠ°ΡΠ·Π°Π»ΡΠ½ΡΠ΅ Π³ΠΎΠ½Π°Π΄ΠΎΡΡΠΎΠΏΠΈΠ½Ρ ΠΠΠ — ΡΠΊΡΡΡΠ°ΠΊΠΎΡΠΏΠΎΡΠ°Π»ΡΠ½ΠΎΠ΅ ΠΎΠΏΠ»ΠΎΠ΄ΠΎΡΠ²ΠΎΡΠ΅Π½ΠΈΠ΅.
Π²-Π₯ΠΠ§ — Π±Π΅ΡΠ° ΡΡΠ±ΡΠ΅Π΄ΠΈΠ½ΠΈΡΠ° Ρ ΠΎΡΠΈΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π³ΠΎΠ½Π°Π΄ΠΎΡΡΠΎΠΏΠΈΠ½Π°.
Π‘ΠΏΠΈΡΠΎΠΊ Π»ΠΈΡΠ΅ΡΠ°ΡΡΡΡ
- 1. ΠΠ°Π»ΠΈΠ½ΠΈΠ½Π° Π‘. Π., Π Π΅Π·Π΅ΡΠ²Ρ ΠΠΎΠ²ΡΡΠ΅Π½ΠΈΡ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΠΠΠ ΠΏΡΠΈ Π»Π΅ΡΠ΅Π½ΠΈΠΈ Π±Π΅ΡΠΏΠ»ΠΎΠ΄ΠΈΡ Ρ ΠΆΠ΅Π½ΡΠΈΠ½ Ρ Π³ΠΈΠ½Π΅ΠΊΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡΠΌΠΈ, Π., 2015 Π³.
- 2. Π’. Π. Π‘ΠΌΠΈΡΠ½ΠΎΠ²Π°, Π. Π. ΠΠ°ΠΌΠ»ΡΠΊ, Π. Π. Π’ΡΠΈΡΠΎΠ½ΠΎΠ²Π°, ΠΡΠΏΠΎΠΌΠΎΠ³Π°ΡΠ΅Π»ΡΠ½ΡΠ΅ ΡΠ΅ΠΏΡΠΎΠ΄ΡΠΊΡΠΈΠ²Π½ΡΠ΅ ΡΠ΅Ρ Π½ΠΎΠ»ΠΎΠ³ΠΈΠΈ ΠΏΡΠΈ ΡΠΈΠ½Π΄ΡΠΎΠΌΠ΅ ΠΏΠΎΠ»ΠΈΠΊΠΈΡΡΠΎΠ·Π½ΡΡ ΡΠΈΡΠ½ΠΈΠΊΠΎΠ², ΠΠΈΠ½ΡΠΊ, 2015 Π³.
- 3. Π‘ΠΌΠΈΡΠ½ΠΎΠ²Π° Π. Π. ΠΡΠΎΠ³Π½ΠΎΠ·ΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ ΠΈΡΡ ΠΎΠ΄Π° ΠΈΠ½Π΄ΡΠΊΡΠΈΠΈ ΠΎΠ²ΡΠ»ΡΡΠΈΠΈ Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠΊ Ρ ΡΠΈΠ½Π΄ΡΠΎΠΌΠΎΠΌ ΠΏΠΎΠ»ΠΈΠΊΠΈΡΡΠΎΠ·Π½ΡΡ ΡΠΈΡΠ½ΠΈΠΊΠΎΠ², Π., 2004 Π³.
- 4. ΠΠ½Π΄ΡΠ΅Π΅Π²Π° Π. Π., Π. Π€. ΠΠ΅ΡΠ½ΠΈΠ½Π°, ΠΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠΈ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΡ Π²ΡΠΏΠΎΠΌΠΎΠ³Π°ΡΠ΅Π»ΡΠ½ΡΡ ΡΠ΅ΠΏΡΠΎΠ΄ΡΠΊΡΠΈΠ²Π½ΡΡ ΡΠ΅Ρ Π½ΠΎΠ»ΠΎΠ³ΠΈΠΉ ΠΏΡΠΈ ΡΠΈΠ½Π΄ΡΠΎΠΌΠ΅ ΠΏΠΎΠ»ΠΈΠΊΠΈΡΡΠΎΠ·Π½ΡΡ ΡΠΈΡΠ½ΠΈΠΊΠΎΠ², «Π’ΡΡΠ΄Π½ΡΠΉ ΠΏΠ°ΡΠΈΠ΅Π½Ρ» № 78, Π., 2005 Π³.
- 5. ΠΠΈΡΠ°ΠΊΠΎΡΡΠ½ Π. Π. Π‘ΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΡΠ΅ ΠΏΠΎΠ΄Ρ ΠΎΠ΄Ρ ΠΊ ΠΈΠ½Π΄ΡΠΊΡΠΈΠΈ ΠΎΠ²ΡΠ»ΡΡΠΈΠΈ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ Ρ Π‘ΠΠΠ―, Π, 2005 Π³.
- 6. Π€Π΅ΡΡΠΊΠΎΠ² Π. Π., Π‘ΠΎΠΌΠΎΠ²Π° Π. Π. ΠΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠΈ ΠΌΠΈΠΊΡΠΎΠΎΠΊΡΡΠΆΠ΅Π½ΠΈΡ ΠΎΠΎΡΠΈΡΠΎΠ² ΠΈ ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΠΈ ΡΠΌΠ±ΡΠΈΠΎΠ½ΠΎΠ² Ρ ΠΆΠ΅Π½ΡΠΈΠ½ Ρ Π‘ΠΠΠ―, Π₯Π°ΡΡΠΊΠΎΠ², 2010 Π³.
- 7. ΠΡΠ°ΠΊΡΠΈΡΠ΅ΡΠΊΠΎΠ΅ ΡΡΠΊΠΎΠ²ΠΎΠ΄ΡΡΠ²ΠΎ ΠΏΠΎ Π»Π΅ΡΠ΅Π½ΠΈΡ ΠΆΠ΅Π½ΡΠΊΠΎΠ³ΠΎ Π±Π΅ΡΠΏΠ»ΠΎΠ΄ΠΈΡ, ΠΎΠ±ΡΡΠ»ΠΎΠ²Π»Π΅Π½Π½ΠΎΠ³ΠΎ ΠΊΡΡΡΠ΅Π½ΠΈΡΠΌΠΈ ΠΏΡΠΎΡΠ΅ΡΡΠ° ΠΎΠ²ΡΠ»ΡΡΠΈΠΈ/ Π’. Π. ΠΠ°Π·Π°ΡΠ΅Π½ΠΊΠΎ ΠΈ Π΄Ρ. ΠΠΎΡΠΊΠ²Π°. 2005.-Π‘. 5−8.
- 8. Π€Π°Π½ΡΠ΅Π½ΠΊΠΎ Π. Π. ΠΠ°Π±ΠΎΡΠ°ΡΠΎΡΠ½Π°Ρ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠ° Π½Π°ΡΡΡΠ΅Π½ΠΈΠΉ ΡΠ΅Π½ΡΡΠ°Π»ΡΠ½ΠΎΠΉ ΡΠ΅Π³ΡΠ»ΡΡΠΈΠΈ ΡΠ΅ΠΏΡΠΎΠ΄ΡΠΊΡΠΈΠ²Π½ΠΎΠΉ ΡΠΈΡΡΠ΅ΠΌΡ/ Π. Π. Π€Π°Π½ΡΠ΅Π½ΠΊΠΎ ΠΡΠΎΠ±Π»Π΅ΠΌΡ ΡΠ΅ΠΏΡΠΎΠ΄ΡΠΊΡΠΈΠΈ. 2001.-№ 1.-Π‘. 100−103.
- 9. Asuncion Π, Caivo R M, San Mil Ian JL, Sancho J. A vila S, Escobar-Morreale HF. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab. 2000; 85:2434−8.
- 10. Azziz R. Woods KS, Reyna R. Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab. 2004; 89:2745−9.
- 11. Diamanti-Kandarakis E, Kouli C’R, Bergiele AT. Filandra FA, Tsianateli TC, Spina GG, et al. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab. 1999; 84:4006−11.
- 12. March W A. Moore VM, Willson KJ, Phillips DI, Norm an RJ, Davies MJ. The prevalence of polycystic ovary syndrome in a com m unity sample assessed under contrasting diagnostic criteria. Hum Reprod. Hum Reprod. 2010 Feb; 25(2):544−51.
- 13. Moran C, Tena G, Moran S, Ruiz P, Reyna R, X. D. Prevalence of polycystic ovary syndrome and related disorders in Mexican women. Gynecol Obstet Invest. 2010; 69:274−80.
- 14. Yildiz BO, Bozdag G, Yapici Z, Esinler I. Yarali II. Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria. Mum Reprod. 2012 Oct; 27(10):3067−73.
- 15. Azziz R, Sanchez LA, Knochenhauer ES, Moran C, Lazenby J, Stephens ΠΠ‘, Taylor K, Boots LR. Androgen excess in women: experience with over 1000 consecutive patients .1 Clin Endocrinol Metab. 2004 Feb;89(2):453−62.
- 16. Azziz R, Carmina E, Devvailly D, Diam anti-Kandarakis E, Escobar-Morreale HF, Futterweit W, Janssen OE, Legro RS, Norm an RJ, Taylor A E, Witchel SF I he Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril. 2009 Feb;91(2):456−88.
- 17. Carmina E, Rosato F, Janni A, Rizzo M, Longo RA. Extensive clinical experience: relative prevalence of different androgen excess disorders in 950 women referred because of clinical hyperandrogenism J Clin Endocrinol Metab. 2006 Jan; 91(1):2−6.
- 18 Hardiraan P, Pillay ΠΠ‘, Atiomo W. Polycystic ovary syndrome and endometrial carcinoma. Lancet 2003; 361:1810.
- 19 Gadducci A, Gargini A, Pal la E, et al. Polycystic ovary syndrome and gynecological cancers: is there a link? Gynecol Endocrinol 2005; 20:200.
- 20 Glucose intolerance in polycystic ovary syndrome — a position statement of the Androgen Excess Society. J Clin Endocrinol Metab. 2007 Dec; 92(12):4546−56.
- 21 Wild S, Pierpoint T, McKeigue P, and Jacobs FI. Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study. Clin. Endocrinol. 2000 52: 595−600
- 22 Randeva H S, Tan BK, Weickert MO, et al. C ardiometabolic aspects of the polycystic ovary syndrome. Endocr Rev 2012; 33:812.
- 23 Zawadzki J, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens J. Haseltine Haseltine F, Haseltine G, eds. Polycystic Ovary Syndrome, ls d. Oxford, England: Blackwell Scientific; 1992:377−384
- 24 Rotterdam ESM RE/ASRMSponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004: 19:41−7.
- 25 Azziz R, Carmina J2, Dewailly D et al. Positions statement: Criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab. 2006 Nov; 91(11):4237−45.
- 26 http://prevention.nih.gov/workshops/2012/pcos/docs/FinalR eport. pdf
- 27 Escobar-Morreale IIF1, Carmina E, Dewailly D et al. E pidemiology, diagnosis and management of hirsutism: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome Society. Hum Reprod Update. 2012 Mar-Apr; 18(2): 146−70.
- 28 Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH, Pasquali R, Welt CK. Diagnosis and treatment of polycystic ovary syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2013 Dec; 98 (12):4565−9.
- 29 Cheewadhanaraks S, Peeyananjarassri K, Cboksuchat Π‘ Clinical diagnosis of hirsutism in Thai women. J Med Assoc Thai. 2004 M ay;87(5):459−63.
- 30 Yildiz BO. Bolour S, Woods K, Moore A, Azziz R. Visually scoring hirsutism. HumReprod Update 2010; 16:51−64.
- 31 Karrer-Voegeli S, Rev F, Reymond MJ, Meuwly JY, Gaillard RC, Gomez F. Androgen dependence of hirsutism, acne, and alopecia imvomen: retrospective analysis of 228 patients investigated for hyperandrogenism. Medicine (Baltim ore). 2009; 88:32−45.
- 32 Rosner W. Position statement: Utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement. J Clin Endocrinol Metab. 2007 Feb: 92(2):405−13,
- 33 Stanczyk F.Z. Diagnosis of hyperandrogenism: Biochemical criteria Best Practice & Research Clinical Endocrinology & Metabolism 2006 Vol. 20, No. 2, pp. 177−191.
- 34 Medical eligibility criteria for contraceptive use. W HO: 4th ed. 2010
- 35 Consensus on infertility treatment related to polycystic ovary syndrome. Thessaloniki ESH R E/A SR MSponsored PCOS Consensus Workshop Group. H um Reprod. 2008 Mar; 23(3):462−77.
- 36 Imam B l, Eijkemans M J. te Velde ER et al. A nomogram to predict the probability of live birth after clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility. Fertil Steril. 2002 Jan;77(1):9 1 -7.
- 37 N IH /N IC H D Reproductive Medicine Network. Effect of letrozole versus clomiphene on live birth in women with anovulatory infertility due to polycystic ovary syndrome (PCOS): a randomized doubleblind multicenter trial. Fertil Steril. 2013; 100
- 38 Farquhar C, Brow n J, Marjoribanks J. Laparoscopic drilling by diathermy or laser for ovulation induction in anovulatory polycystic ovary syndrome. Cochrane Database Syst Rev. 2012 Jun 13; 6: C D 1 122.
- 39 Bayram N, vanWely M, Kaaijk EM, Bossuyt PM, van derVeen F. Using an electrocautery strategy or recombinant follicle stim ulatinghorm one to induce ovulation in polycystic ovary syndrome: randomised controlled trial. BMJ 2004; 328:192
- 40 Mohammed E. Hyperprolactenaemia after laparoscopic ovarian drilling: an unknown phenomenon. Reprod Endocrin 2005;3:3.
- 41 American Society for Reproductive Medicine. (2011). Frequently asked questions about infertility. Retrieved December 22, 2011,
- 42 ACOG. (2011). Polycystic ovary syndrome. Retrieved May 10, 2012, from (PDF — 73 KB)
- 43 Moran, L. J., Pasquali, R., Teede, H. J., Hoeger, K. M., & Norman, R. J. (2009). Treatment of obesity in polycystic ovary syndrome: A position statement of the Androgen Excess and Polycystic Ovary Syndrome Society. Fertility and Sterility, 92, 1966;1982.
- 44 Legro, R. S. (2007). Pregnancy considerations in women with polycystic ovary syndrome. Clinical Obstetrics and Gynecology, 50, 295−304.
- 45 Kiddy, D.S., Hamilton-Fairley, D., Bush, A., Short, F., Anyaoku, V., Reed, M.J., et al. (1992). Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clinical Endocrinology (Oxford), 36, 105−111.
- 46 National Cancer Institute. (2006). Oral contraceptives and cancer risk: Questions and answers. Retrieved December 22, 2011,
- 47 Goodarzi, M. O., Dumesic, D. A., Chazenbalk, G., & Azziz, R. (2011). Polycystic ovary syndrome: Etiology, pathogenesis and diagnosis. Nature Reviews Endocrinology, 7, 219−231.
- 48 Johnson, N. (2011). Metformin is a reasonable first-line treatment option for non-obese women with infertility related to anovulatory polycystic ovary syndrome—A meta-analysis of randomised trials. Australian and New Zealand Journal of Obstetrics & Gynaecology, 51, 125−129.
- 49 Vause, T. D., Cheung, A. P., Sierra, S., Claman, P., Graham, J., Guillemin, J. A., et al.; Society of Obstetricians and Gynecologists of Canada (2010). Ovulation induction in polycystic ovary syndrome. Journal of Obstetrics and Gynaecology Canada, 32, 495−502.
- 50 U.S. Food and Drug Administration (FDA). (2000). VANIQATM (eflornithine hydrochloride) cream, 13.9%. Retrieved December 22, 2011
- 51 He, D., & Jiang, F. (2011). Meta-analysis of letrozole versus clomiphene citrate in polycystic ovary syndrome. Reproductive Biomedicine Online, 23, 91−96.
- 52 FDA. (2010). Femara (letrozole) tablets: Highlights of prescribing information. Retrieved December 22, 2011,
- 53 Bielah Π. M. Amenorrhea/ K.M.Bielak Π Medicine Journal. 2001. Vol. 2. P. 125−132.
- 54 August 2002, Washington, DC. / ZT Bloomgarden II Diabetes Care.
- 55 Central Adiposity Determines Prevalence Differences of the Metabolic Syndrome. / C. Lorenzo, M. Serrano-Rios, M. T. Martinez-Larrad et al. ll Obes. Res.-2003.-Vol. 11.-N.12.-P. 1480−1487.
- 56 Kidson W. Polycystic ovary syndrome: a new direction in treatment/ W. Kidson IIMJA. 2005. — Vol. 169. — P. 537−540.